MedTrace Logo

A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101

NCT04947124 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2025-01-20

No results posted yet for this study

Summary

Safety and tolerability study of 2 concentrations of QLS-101 for adult subjects with Sturge Weber Syndrome (SWS)-related glaucoma due to elevated episcleral venous pressure (EVP).

Conditions

Interventions

DRUG

QLS-101ophthalmic solution 1%

QLS-101ophthalmic solution 1.0%

DRUG

QLS-101ophthalmic solution 2%

QLS-101ophthalmic solution 2.0%

Sponsors & Collaborators

  • Qlaris Bio, Inc.

    lead INDUSTRY

Principal Investigators

  • B. Wirostko, M.D. · Qlaris Bio, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-19
Primary Completion
2022-06-06
Completion
2022-08-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04947124 on ClinicalTrials.gov